AVEO Does AVEO remind anyone of EXEL? AVEO has had redemption with Tivinabid. The drug is ready for approval in EU for possible first line renal cancer. Low toxicity profile and use in combination could be a big disrupter in space. Appears really undervalued with near term catalysts. Any additional viewpoints desired?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.